184 related articles for article (PubMed ID: 38297200)
21. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
[TBL] [Abstract][Full Text] [Related]
22. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
[TBL] [Abstract][Full Text] [Related]
23. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.
Lobo ML; Esteves F; de Sousa B; Cardoso F; Cushion MT; Antunes F; Matos O
PLoS One; 2013; 8(8):e70619. PubMed ID: 23940606
[TBL] [Abstract][Full Text] [Related]
25. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
[TBL] [Abstract][Full Text] [Related]
26. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
[TBL] [Abstract][Full Text] [Related]
28. Use of trimethoprim-sulfamethoxazole in a patient with G6PD deficiency for treating Pneumocystis jirovecii pneumonia without haemolysis: Case report and literature review.
Lu YW; Chen TC
J Clin Pharm Ther; 2020 Dec; 45(6):1483-1485. PubMed ID: 32648956
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.
Li H; Huang H; He H
BMC Pulm Med; 2016 Nov; 16(1):144. PubMed ID: 27835947
[TBL] [Abstract][Full Text] [Related]
30. Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies.
Hammarström H; Krifors A; Athlin S; Friman V; Golestani K; Hällgren A; Otto G; Oweling S; Pauksens K; Kinch A; Blennow O
Clin Infect Dis; 2023 Feb; 76(3):e1252-e1260. PubMed ID: 35594562
[TBL] [Abstract][Full Text] [Related]
31. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
Geerlinks AV; Campigotto A; Science M; Gupta S
Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
[TBL] [Abstract][Full Text] [Related]
32. No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study.
Huang Y; He X; Chen H; Harypursat V; Lu Y; Yuan J; Nie J; Liu M; Yu J; Zhang Y; Jiang Z; Qin Y; Xu L; Zhou G; Zhang D; Chen X; Zheng B; Chen Y
Infect Dis Ther; 2022 Feb; 11(1):543-557. PubMed ID: 35050490
[TBL] [Abstract][Full Text] [Related]
33. Sub-therapeutic trimethoprim and sulfamethoxazole plasma concentrations during continuous venovenous hemofiltration in a patient with COVID-19 and pulmonary
le Noble JLML; Foudraine N; van der Elst KCM; Bouwman S
Int J Clin Pharmacol Ther; 2023 Nov; 61(11):525-530. PubMed ID: 37489071
[TBL] [Abstract][Full Text] [Related]
34. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
[TBL] [Abstract][Full Text] [Related]
35. Pneumocystis jirovecii: a review with a focus on prevention and treatment.
Weyant RB; Kabbani D; Doucette K; Lau C; Cervera C
Expert Opin Pharmacother; 2021 Aug; 22(12):1579-1592. PubMed ID: 33870843
[No Abstract] [Full Text] [Related]
36. Clinical descriptive analysis of severe
Xie D; Xu W; You J; Yuan X; Li M; Bi X; Zhang K; Li H; Xian Y
Bioengineered; 2021 Dec; 12(1):1264-1272. PubMed ID: 33896387
[No Abstract] [Full Text] [Related]
37. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
[TBL] [Abstract][Full Text] [Related]
38. Clinical-epidemiological characteristics of Pneumocystis jirovecii pneumonia in a tertiary hospital in Spain.
Martín Pedraz L; Carazo Gallego B; Moreno Pérez D
An Pediatr (Engl Ed); 2021 Jul; 95(1):4-10. PubMed ID: 34154986
[TBL] [Abstract][Full Text] [Related]
39. Clinical features and diagnostic value of metagenomic next -generation sequencing in five cases of non-HIV related
Niu J; Wang J; Jia P; Zhang M; Wei E
Front Cell Infect Microbiol; 2023; 13():1132472. PubMed ID: 37009508
[TBL] [Abstract][Full Text] [Related]
40. Single-center retrospective analysis of Pneumocystis jirovecii pneumonia in patients after deceased donor renal transplantation.
Zou J; Wang T; Qiu T; Zhou J; Chen Z; Ma X; Jin Z; Xu Y; Zhang L
Transpl Immunol; 2022 Jun; 72():101593. PubMed ID: 35367619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
